All In Biotech

Drug Trial Radar · NCT05200364

A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer

A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers)

Last checked: Nov 19, 2026Latest source record: Sep 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

58

Actual

Start

Mar 22, 2022

Primary completion

Jun 1, 2025

Study completion Jun 1, 2025

Sponsor

Lead sponsor
Sutro Biopharma, Inc.Industry
Sponsor type
Industry
First posted
Jan 20, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 1 trial to study the safety, pharmacokinetic and Preliminary Efficacy of STRO-002 in combination with Bevacizumab.

Conditions

  • Ovarian Cancer
  • Ovarian Carcinoma
  • Ovary Cancer
  • Fallopian Tube Cancer
  • Primary Peritoneal Carcinoma

Interventions

  • STRO-002Drug

    intravenous antibody drug conjugate

  • BevacizumabDrug

    anti-VEGF agent

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 - Safety and tolerability of STRO-002/bevacizumab as a combination therapyTime frame: From baseline through end of study (approximately 24 months)
  2. Part 1 - Determine the recommended phase 2 dose (RP2D) of STRO-002/bevacizumabTime frame: From baseline through end of study (approximately 24 months)

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • University of South Florida,

    Tampa, Florida

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Tennessee Oncology

    Nashville, Tennessee

  • Virginia Cancer Specialists

    Fairfax, Virginia

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.